News

Exploring New Horizons with Oncotelic's Deciparticle™ Platform

Exploring New Horizons with Oncotelic's Deciparticle™ Platform

Oncotelic and Sapu Nano Launch Revolutionary Deciparticle™ Nanomedicine

In a game-changing development, Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has partnered with Sapu Nano to unveil their innovative Deciparticle™ platform. This groundbreaking technology is designed to effectively formulate a variety of hydrophobic drugs, including macrolide mTOR inhibitors and polyketides, enabling enhanced delivery methods for those with intravenous (IV) needs.

Key Findings Highlight Enhanced Drug Formulation Capabilities

Recent data presented by Sapu Nano reveals that the Deciparticle™ technology excels at crafting nanoparticles with a size of under 20 nm, broadening the scope of therapies it can support. This robust capability allows the encapsulation of numerous hydrophobic therapeutics while ensuring consistency and stability, a major leap forward in the nanomedicine field.

Understanding the Deciparticle™ Platform's Versatility

The Deciparticle™ platform has been proven to create effective formulations of macrolide drugs, which are crucial in immunosuppression. Five clinically significant macrolide immunosuppressants, namely Sirolimus, Temsirolimus, Ridaforolimus, Umirolimus, and Everolimus, are now stable within Deciparticle™ formulations. This versatility stems from the platform's ability to maintain nanoparticle integrity despite structural diversities in these compounds.

Exploring Additional Therapeutic Class Capabilities

Moreover, the Deciparticle™ technology effectively encapsulates ascomycin macrolactams such as Tacrolimus and Pimecrolimus, demonstrating a flexible approach to drug design. Interestingly, while Tacrolimus formed stable nanoparticles, Pimecrolimus exceeded the size limit, showcasing the platform's design boundaries.

Expanding Horizons: Peptides and Other Drugs

One of the standout features of the Deciparticle™ platform is its capacity to work with various peptide types. Critical peptide classes like Cyclosporine A and Exenatide have been successfully encapsulated, illustrating the platform's adaptability. Such formulations are vital in ensuring effective delivery for peptide-based therapies, which often face solubility challenges.

Manufacturing and Scalability: A Focus on Quality

The success of the Deciparticle™ platform is supported by Sapu Nano's state-of-the-art ISO-5 cGMP manufacturing facility, which ensures high-quality production standards. Processes such as one-pot bulk manufacturing, sterile filtration, and automated fill/finish contribute to the platform’s efficiency. Notably, this enables rapid progression from formulation to clinical trial supplies, supporting multiple Investigational New Drug (IND) applications each year.

Advancing Drug Delivery Technologies

As stated by Dr. Vuong Trieu, CEO of Sapu Nano, the Deciparticle™ platform represents a significant shift away from traditional delivery methods, proving effective for a wide range of hydrophobic substances previously hindered by delivery issues. This advancement demonstrates a commitment to enhancing drug delivery across various therapeutic areas, including oncology and immunology.

Conclusion: A Bright Future for Nanomedicine

The Deciparticle™ platform is not just a technological advancement; it embodies a broader vision for the future of drug delivery in medicine. With ongoing research and increasing capabilities, Oncotelic is well-positioned to make meaningful improvements in the treatment of patients, particularly in areas where existing therapies have fallen short.

About Sapu Nano

Sapu Nano continues to lead in developing Deciparticle™ nanomedicine, seeking to optimize hydrophobic drug delivery. Their commitment to innovation is evident in their robust cGMP manufacturing capabilities, facilitating the rapid transition from research to clinical application.

Frequently Asked Questions

What is the Deciparticle™ platform?

The Deciparticle™ platform is an advanced nanotechnology enabling the formulation of a wide array of hydrophobic drugs into stable nanoparticles for better drug delivery.

What types of drugs can be formulated using this technology?

This platform supports various classes of drugs, including macrolide mTOR inhibitors, cyclic and linear peptides, and ascomycin macrolactams.

How does the manufacturing process work?

Sapu Nano employs an ISO-5 cGMP facility that supports efficient processes such as one-pot manufacturing and automated filling, aimed at quality and scalability.

Who benefits from the Deciparticle™ technology?

This technology primarily benefits patients requiring improved drug delivery options, particularly in oncology and immunology therapies.

Who is Oncotelic Therapeutics, Inc.?

Oncotelic Therapeutics, Inc. is a biotechnology company focused on enhancing treatment outcomes in cancer patients, emphasizing pediatric cancers and innovative drug delivery systems.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 96

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 113

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading
Webster First Takes Aim at the Youth Money Literacy Gap

Updated Category News Views 86

Money mistakes get expensive long before anyone calls them mistakes. That is the uncomfortable point beneath Webster First Federal Credit Union CEO John Thomasian's November 20, 2026 discussion of financial literacy: plenty of young adults are entering the real financial world with a card, a loan offer, and a phone full of banking apps, but no sturdy framework for using...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 121

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 167

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 49

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 162

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading

Top 5 Most Recently Viewed Articles

Beta Glucan Market Set to Exceed USD 31 Billion by 2030

Updated Category News Views 56

Exploring the Growth of the Beta Glucan Market The beta glucan market is experiencing remarkable growth, largely driven by increasing awareness of its health benefits. More and more consumers are recognizing the importance of supporting their immune systems and managing cholesterol levels, which has led to a surge in demand across numerous sectors, including...

Continue Reading
AiPPT.com: Crafting the Next Era of AI-Driven Presentations

Updated Category News Views 177

Transforming Presentations with AiPPT.com In the evolving landscape of digital work, AiPPT.com stands out as a leading provider of AI-native tools that are reshaping the way presentations are crafted. As an advanced AI presentation maker, AiPPT.com is committed to enhancing user experiences by making the process of creating engaging and professional presentations much...

Continue Reading
Acme Mills Launches Natura: Revolutionizing Sustainable Fabrics

Updated Category News Views 244

Revolutionizing Textile Innovation with Natura Acme Mills Company, a recognized pioneer in textile manufacturing, has proudly unveiled its latest innovation, Natura. This new line of bio-based polylactic acid (PLA) fabrics aims to replace traditional petroleum-based materials such as PET, PP, and Nylon. With Natura, Acme Mills is not just promoting a product; it is...

Continue Reading
Class Action Alert for C3.ai, Inc. Investors - Join Now!

Updated Category News Views 123

Opportunity for C3.ai, Inc. Shareholders to Join Class Action Attention, shareholders of C3.ai, Inc. (NYSE: AI). A significant class action suit is currently underway, and your involvement could be crucial. If you purchased shares during the class period, there may be an opportunity for you to participate in a recovery process without the requirement of being a lead...

Continue Reading
EyePoint Pharmaceuticals: Innovations and Financial Insights

Updated Category News Views 224

EyePoint Pharmaceuticals Set to Showcase Q2 Financials EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pioneering company dedicated to developing advanced therapeutics for serious retinal diseases, plans to share its second quarter 2025 financial results. This announcement will be accompanied by a live conference call and webcast on a scheduled day, promising to provide...

Continue Reading